本报告为摩根士丹利对北美生物制药行业的周度跟踪更新，基于IQVIA处方（Rx）数据对全美药品市场进行综合分析。截至10月2日当周，美国市场总处方量（TRx）同比增速为+2.0%，高于去年同期的+0.8%和过去12周的+1.8%；滚动4周TRx同比为0.0%，滚动12周为+1.8%；扩展单位（EUTRx）周度同比+1.7%，低于TRx增速。报告重点分析多款新上市药物：吉利德Yeztugo（来那卡帕韦，2025年6月18日获批用于PrEP）最新周口服+注射总处方约2100，其中注射剂约1380，持续率>70%，已获95%支付方覆盖；强生Icotyde（与Protagonist合作，2026年3月18日获批治疗中重度斑块状银屑病）周处方约1730，商业支付方覆盖超50%；
This report is Morgan Stanley's weekly update on the North American biopharma sector, providing a comprehensive US drug market analysis based on IQVIA prescription (Rx) data. For the week ending Oct 2, US total market weekly TRx YoY growth was +2.0% vs. +0.8% a year ago and +1.8% over the past 12 weeks; rolling 4-week TRx YoY was 0.0% and rolling 12-week TRx YoY was +1.8%. Extended unit (EUTRx) weekly YoY growth was +1.7%, below TRx YoY. The report highlights several recent launches: Gilead's Yeztugo (lenacapavir, approved for PrEP on 6/18/2025) with latest week total TRx (oral + injectable) of ~2,100, of which injectable ~1,380, a persistence rate >70% and 95% payor coverage; JNJ's Icotyde (partnered with Protagonist, approved for moderate-to-severe plaque psoriasis on 3/18/26) with ~1,730 prescriptions and commercial payer coverage now exceeding 50%; Merck's Lipfendra (enlicitide, once-daily oral PCSK9i, approved 7/16/26) at ~2,660 prescriptions in the tenth week post-launch;